Pulmonary Complications Secondary to Immune Checkpoint Inhibitors
Joint Authors
Duma, Narjust
Albitar, Hasan Ahmad Hasan
Leventakos, Konstantinos
Gallo De Moraes, Alice
Source
International Journal of Chronic Diseases
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-04-24
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Background.
Immune checkpoint inhibitors (ICI) have changed the landscape in the treatment of a number of cancers.
Immune-related adverse events (irAEs) have emerged as a serious clinical problem with the use of ICI.
Methods.
All oncology patients diagnosed with pulmonary complications secondary to ICI at Mayo Clinic Rochester from January 1, 2012 to December 31, 2018 were reviewed.
Demographics, comorbidities, smoking, and oncologic history were analyzed.
Results.
A total of 10 patients developed pulmonary complications secondary to ICI.
Seven patients were men (70%), and the median age at diagnosis was 61.5 (IQR 55.8-69.3) years.
All patients had stage IV disease.
Melanoma was the most common malignancy.
Seven (70%) patients had a positive smoking history, and 6 (60%) were obese (BMI>30).
Most cases were grade 2 pneumonitis (70%).
One patient with grade 4 pneumonitis required endotracheal intubation and a prolonged course of systemic corticosteroids (>30 days).
Eight (80%) patients received prior radiation therapy.
The median time from initiation of ICI to pneumonitis diagnosis was 3.5 months.
Conclusion.
Melanoma was the most common malignancy, the majority of patients had grade 2 pneumonitis and required treatment with steroids, and all patients affected by ICI-related pneumonitis had stage IV malignancy.
Potential risk factors included smoking history, prior radiotherapy, obesity, and advance stage at the time of ICI initiation.
Extrapulmonary irAEs are common in patients with pneumonitis.
American Psychological Association (APA)
Albitar, Hasan Ahmad Hasan& Duma, Narjust& Leventakos, Konstantinos& Gallo De Moraes, Alice. 2020. Pulmonary Complications Secondary to Immune Checkpoint Inhibitors. International Journal of Chronic Diseases،Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1169303
Modern Language Association (MLA)
Albitar, Hasan Ahmad Hasan…[et al.]. Pulmonary Complications Secondary to Immune Checkpoint Inhibitors. International Journal of Chronic Diseases No. 2020 (2020), pp.1-5.
https://search.emarefa.net/detail/BIM-1169303
American Medical Association (AMA)
Albitar, Hasan Ahmad Hasan& Duma, Narjust& Leventakos, Konstantinos& Gallo De Moraes, Alice. Pulmonary Complications Secondary to Immune Checkpoint Inhibitors. International Journal of Chronic Diseases. 2020. Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1169303
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1169303